Number of Participants Diagnosed With Sarcoidosis by Bronchoscopic Transbronchial Needle Aspiration After COVID- 2019 .

Sponsor

Ain Shams University (Other)

Overall Status

Completed

CT.gov ID

NCT06043882

Collaborator

(none)

Enrollment

Location

6.9

Actual Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this observational study is to learn about sarcoidosis development after COVID-19 infection.

The main question it aims to answer is:

prevalence of Sarcoidosis among patients previously infected with COVID-19.

Participants will:

provide previous positive RT-PCR for COVID-19
Have computed tomography of the Chest with suggestive findings of sarcoidosis
Have bronchoscopic guided biopsies and pathological analysis to detect number of patients with sarcoidosis.

Condition or Disease	Intervention/Treatment	Phase
Sarcoidosis COVID-19	Procedure: flexible bronchoscopy

Detailed Description

This prospective cross sectional study was performed on a total of 55 patients with mediastinal and /or hilar lymphadenopathy with or without lung infiltrates referred to Bronchoscopy unit , Chest department, Ain-Shams University hospital for biopsy taking and diagnosis.

All patients were subjected to the following : history taking , clinical examination , radiological assessment by computed tomography (CT )chest , fiberoptic bronchoscopy where biopsies were taken either by conventional-Trans-bronchial needle aspiration (c-TBNA) , endo-bronchial ultrasound (EBUS-TBNA) or direct forceps biopsies and sent for histopathological examination and if the patient had past history of COVID-19 infection with previous positive reverse transcriptase- polymerase chain reaction assay (RT-PCR).

Study Design

Study Type:

Observational

Actual Enrollment :

55 participants

Observational Model:

Case-Crossover

Time Perspective:

Prospective

Official Title:

Number of Participants Diagnosed With Sarcoidosis by Bronchoscopic Transbronchial Needle Aspiration After Corona Virus Disease of 2019 Infection.

Actual Study Start Date :

Nov 1, 2022

Actual Primary Completion Date :

Apr 30, 2023

Actual Study Completion Date :

May 30, 2023

Arms and Interventions

Arm	Intervention/Treatment
the relation between COVID-19 infection and the development of sarcoidosis . All patients were subjected to the following : history taking , clinical examination , radiological assessment by CT chest , fiberoptic bronchoscopy where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination and if the patient had past history of COVID-19 infection with previous positive RT-PCR.	Procedure: flexible bronchoscopy fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination

Arm

Intervention/Treatment

the relation between COVID-19 infection and the development of sarcoidosis .

All patients were subjected to the following : history taking , clinical examination , radiological assessment by CT chest , fiberoptic bronchoscopy where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination and if the patient had past history of COVID-19 infection with previous positive RT-PCR.

Procedure: flexible bronchoscopy

fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination

Outcome Measures

Primary Outcome Measures

Number and risk factors of sarcoidosis development after COVID -19 infection as diagnosed by TBNA guided tissue biopsies in bronchoscopy unit, chest department, Ain Shams university. [6 months]
Number of COVID-19 patients diagnosed by TBNA guided biopsies as having granulomatous tissue suggesting sarcoidosis development, and risk factors that associate its development.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All adult patients with previous positive RT-PCR for COVID -19 and CT chest findings of mediastinal and or hilar lymphadenopathy with or without lung infiltrate will be included. .